Indivior's Monthly Injectable Buprenorphine Wins Panel Backing; US FDA May Limit Dosage
Executive Summary
Advisory committee votes 18 to 1 for approval of the opioid abuse disorder treatment with restricted distribution; members advise post-market studies, registry.